Results 61 to 70 of about 51,741 (305)

Side Effects Related to BNT162b2 and CoronaVac Vaccine Requiring Emergency Department Visit

Avicenna Journal of Medicine, 2022
Background Currently, the most effective method in the fight against coronavirus disease 2019 (COVID-19) is vaccination against the disease. However, there are hesitations among society concerning the safety and side effects of COVID-19 vaccines.
Erdal Yavuz, Kasim Turgut, Umut Gulacti, İrfan Aydın, Oguzhan Ozcan, Cihad Sonmez, Ebru Arslan   +6 more
doaj   +1 more source

Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis [PDF]

, 2022
Background: Patients with cancer are considered a priority group for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccination given their high risk of contracting severe Coronavirus Disease 2019 (COVID-19).
Barrientos-Gutierrez, T., Becerril-Gaitan, A., Ferrigno, A. S., Lambertini, M., Mesa-Chavez, F., Tagliamento, M., Vaca-Cartagena, B. F., Villarreal-Garza, C.   +7 more
core   +1 more source

Immunogenicity and reactogenicity of heterologous COVID-19 vaccination in pregnant women

Human Vaccines & Immunotherapeutics, 2023
This open-labeled non-inferiority trial evaluated immunogenicity and reactogenicity of heterologous and homologous COVID-19 vaccination schedules in pregnant Thai women.
Chenchit Chayachinda, Kanokwaroon Watananirun, Chayawat Phatihattakorn, Sanitra Anuwutnavin, Suvimol Niyomnaitham, Wanatpreeya Phongsamart, Keswadee Lapphra, Orasri Wittawatmongkol, Supattra Rungmaitree, Laddawan Jansarikit, Kobporn Boonnak, Patimaporn Wongprompitak, Sansnee Senawong, Avishek Upadhya, Zheng Quan Toh, Paul V. Licciardi, Kulkanya Chokephaibulkit   +16 more
doaj   +1 more source

Is a single COVID-19 vaccine dose enough in convalescents ?

Human Vaccines & Immunotherapeutics, 2021
SARS-CoV-2 has infected more than 122 million persons worldwide. Most currently licensed COVID-19 vaccines require a two-dose course and many health systems are on a shortage of doses.
Daniele Focosi, Andreina Baj, Fabrizio Maggi   +2 more
doaj   +1 more source

Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases [PDF]

, 2022
Patients with inflammatory rheumatic diseases (IRD) are at increased risk for worse COVID-19 outcomes. Identifying whether mRNA vaccines differ in immunogenicity and examining the effects of immunomodulatory treatments may support COVID-19 vaccination ...
Andrey, Diego O, Berger, Christoph T, Ciurea, Adrian, Finckh, Axel, Lauper, Kim, Lescuyer, Pierre, Maletic, Tanja, Möller, Burkhard, Polysopoulos, Christos, Raptis, Catherine E, Riek, Myriam, Rubbert-Roth, Andrea, Safford, Judith, Scherer, Almut, von Loga, Isabell, Vuilleumier, Nicolas   +15 more
core   +1 more source

Pfizer SARS-CoV-2 BNT162b2 mRNA vaccination (BNT162b2) has no adverse effect on elective oocyte cryopreservation outcomes

Reproductive BioMedicine Online, 2022
Do elective oocyte cryopreservation outcomes in women 1-13 months after SARS-CoV-2 vaccination alter compared with unvaccinated women and do different time intervals between vaccination and ovarian stimulation impact these outcomes?This retrospective cohort study, conducted in a university-affiliated IVF centre, included 232 elective oocyte ...
Gilad Karavani, Henry H. Chill, Aharon Dick, Cherut Meirman, Einat Gutman-Ido, Shmuel Herzberg, Assaf Ben-Meir, Tal Imbar   +7 more
openaire   +2 more sources

Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. [PDF]

, 2021
BACKGROUND: The Pfizer-BioNTech (BNT162b2) and the Oxford-AstraZeneca (ChAdOx1 nCoV-19) COVID-19 vaccines have shown excellent safety and efficacy in phase 3 trials. We aimed to investigate the safety and effectiveness of these vaccines in a UK community
Antonelli, M, Canas, LS, Capdevila, J, Chan, AT, Drew, DA, Goodman, AL, Graham, MS, Hammers, A, Hu, C, Joshi, AD, Klaser, K, Louca, P, Mangino, M, May, A, Menni, C, Merino, J, Modat, M, Molteni, E, Murray, B, Nguyen, LH, Ourselin, S, Polidori, L, Selvachandran, S, Spector, TD, Steves, CJ, Sudre, CH, Valdes, AM, Wolf, J   +27 more
core  

Antibody Response Induced by BNT162b2 and mRNA-1273 Vaccines against the SARS-CoV-2 in a Cohort of Healthcare Workers [PDF]

, 2022
The aim of this study was to characterize the antibody response induced by SARS-CoV-2 mRNA vaccines in a cohort of healthcare workers. A total of 2247 serum samples were analyzed using the Elecsys(®) Anti-SARS-CoV-2 S-test (Roche Diagnostics ...
Amengual Guedan, Maria Jose, Berenguer-Llergo, Antoni, Calvet, Joan, Delgado, Juan Francisco, Espasa, Mateu, Gratacós, Jordi, Julià, Germà, Navarro Rubio, Gemma, Navarro, Marta, Peña, Pilar, Rodríguez, Sara, Serrano, Rosa M., Sánchez, Noemí, Van Den Eynde, Eva   +13 more
core   +1 more source

BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19

Nature Communications, 2022
Abstract Heterologous prime/boost vaccination with a vector-based approach (ChAdOx-1nCov-19, ChAd) followed by an mRNA vaccine (e.g. BNT162b2, BNT) has been reported to be superior in inducing protective immunity compared to repeated application of the same vaccine.
Georg M. N. Behrens, Joana Barros-Martins, Anne Cossmann, Gema Morillas Ramos, Metodi V. Stankov, Ivan Odak, Alexandra Dopfer-Jablonka, Laura Hetzel, Miriam Köhler, Gwendolyn Patzer, Christoph Binz, Christiane Ritter, Michaela Friedrichsen, Christian Schultze-Florey, Inga Ravens, Stefanie Willenzon, Anja Bubke, Jasmin Ristenpart, Anika Janssen, George Ssebyatika, Verena Krähling, Günter Bernhardt, Markus Hoffmann, Stefan Pöhlmann, Thomas Krey, Berislav Bošnjak, Swantje I. Hammerschmidt, Reinhold Förster   +27 more
openaire   +4 more sources

Protection by a Fourth Dose of BNT162b2 against Omicron in Israel

New England Journal of Medicine, 2022
Background On January 2, 2022, Israel began administering a fourth dose of BNT162b2 vaccine to persons 60 years of age or older. Data are needed regarding the effect of the fourth dose on rates of confirmed severe acute respiratory syndrome coronavirus 2
Y. Bar-On, Y. Goldberg, Michael I. Mandel, O. Bodenheimer, Ofra Amir, L. Freedman, S. alroy-Preis, N. Ash, A. Huppert, R. Milo   +9 more
semanticscholar   +1 more source